| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.016 | 0.9 |